Skip to content
Study details
Enrolling now

4-Aminopyridine Treatment for Nerve Injury

John Elfar
NCT IDNCT03701581ClinicalTrials.gov data as of Apr 2026
Phase

Phase 2/3

Target enrollment

70

Study length

about 7.6 years

Ages

45–75

Sex

Male only

Locations

2 sites in AZ, NY

About this study

This trial is testing whether 4-aminopyridine (4-AP) can help with recovery after nerve injuries. The treatment will be compared to a placebo.

Based on ClinicalTrials.gov records.

What participants do

  • 1.Placebo
  • 2.Take 4-Aminopyridine
PhasePhase 2/Phase 3
Drug4-Aminopyridine
Primary goalMichigan Incontinence Sympton Index (M-ISI) (change over time)

Participation effort

Estimated from trial records. Details can vary by site.

Time + visits
Low6%
Logistics
Moderate50%

Logistics difficulty varies by site location and availability.

Trial highlights

Treatment details

Auto-extracted from trial records to preview treatments and outcomes.

Drug classes

fampridine

Endpoints

Primary: Michigan Incontinence Sympton Index (M-ISI) (change over time)

Body systems

Oncology